327 related articles for article (PubMed ID: 21423426)
1. The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.
Khandelwal PJ; Moussa CE
Front Psychiatry; 2010; 1():15. PubMed ID: 21423426
[TBL] [Abstract][Full Text] [Related]
2. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Kumar P; Pradhan K; Karunya R; Ambasta RK; Querfurth HW
J Neurochem; 2012 Feb; 120(3):350-70. PubMed ID: 22098618
[TBL] [Abstract][Full Text] [Related]
3. Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Moussa CE
J Mol Neurosci; 2009 Jan; 37(1):25-36. PubMed ID: 18561034
[TBL] [Abstract][Full Text] [Related]
4. Parkin promotes intracellular Abeta1-42 clearance.
Burns MP; Zhang L; Rebeck GW; Querfurth HW; Moussa CE
Hum Mol Genet; 2009 Sep; 18(17):3206-16. PubMed ID: 19483198
[TBL] [Abstract][Full Text] [Related]
5. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
6. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
7. Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model.
Khandelwal PJ; Dumanis SB; Feng LR; Maguire-Zeiss K; Rebeck G; Lashuel HA; Moussa CE
Mol Neurodegener; 2010 Nov; 5():47. PubMed ID: 21050448
[TBL] [Abstract][Full Text] [Related]
8. Interface between tauopathies and synucleinopathies: a tale of two proteins.
Galpern WR; Lang AE
Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
[TBL] [Abstract][Full Text] [Related]
9. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
10. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
11. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
Menéndez J; Rodríguez-Navarro JA; Solano RM; Casarejos MJ; Rodal I; Guerrero R; Sánchez MP; Avila J; Mena MA; de Yébenes JG
Hum Mol Genet; 2006 Jul; 15(13):2045-58. PubMed ID: 16698879
[TBL] [Abstract][Full Text] [Related]
13. Diminished parkin solubility and co-localization with intraneuronal amyloid-β are associated with autophagic defects in Alzheimer's disease.
Lonskaya I; Shekoyan AR; Hebron ML; Desforges N; Algarzae NK; Moussa CE
J Alzheimers Dis; 2013; 33(1):231-47. PubMed ID: 22954671
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
Hasegawa M
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
[TBL] [Abstract][Full Text] [Related]
16. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Fournier M; Vitte J; Garrigue J; Langui D; Dullin JP; Saurini F; Hanoun N; Perez-Diaz F; Cornilleau F; Joubert C; Ardila-Osorio H; Traver S; Duchateau R; Goujet-Zalc C; Paleologou K; Lashuel HA; Haass C; Duyckaerts C; Cohen-Salmon C; Kahle PJ; Hamon M; Brice A; Corti O
PLoS One; 2009 Aug; 4(8):e6629. PubMed ID: 19680561
[TBL] [Abstract][Full Text] [Related]
17. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
18. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H
Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732
[TBL] [Abstract][Full Text] [Related]
19. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
20. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.
Gu J; Chen F; Iqbal K; Gong CX; Wang X; Liu F
J Biol Chem; 2017 Jun; 292(25):10600-10612. PubMed ID: 28487370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
